It’s looking like there won’t be any more generic, crush-resistant versions of Endo Pharmaceuticals Inc.’s opioid painkiller Opana ER on the market for a while.
And a recent court ruling upholding the validity of a patent covering Opana ER is likely to keep proposed generic crush-proof versions made by Teva Pharmaceuticals USA Inc. and Amneal Pharmaceuticals LLC off the market until late 2029. That’s when Mallinckrodt LLC’s patent on the drug expires.
Opioid analgesics like Opana ER can be highly addictive and the crush-resistant formulation of the painkiller is designed to make the product more difficult to abuse and misuse. The crush-resistant feature is becoming more important to the market as public concern grows about the increasing incidence of opioid abuse in the U.S.
Four years ago, Endo withdrew its original formula of Opana ER from the market and replaced it with Opana ER CRF (crush-resistant formulation).
Currently, Impax Laboratories Inc. makes the only generic version of the crush-resistant version of Opana ER on the market, an authorized generic version that it started marketing in January 2013.
Based on the latest court ruling, it looks like things are going to stay that way for some time to come.
A copy of the court’s Oct. 7 ruling is at http://src.bna.com/jix.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)